Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE)

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies for setrusumab (UX143) in treating Osteogenesis Imperfecta, leading to a significant drop in stock price [1][2][3] Group 1: Study Results - The Phase III Orbit and Cosmic studies did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates, respectively [2] - Although secondary endpoints showed improvements in bone material density, these did not correlate with a statistically significant reduction in fractures in either study [2] Group 2: Financial Impact - Following the announcement of the study results, Ultragenyx's stock price fell by $14.87, a decrease of 43.49%, opening at $19.32 per share on December 29, 2025 [3] - The stock decline has resulted in a new 52-week low, significantly below the previous low of $25.81 [3] Group 3: Company Response - Ultragenyx has indicated it will implement significant expense reductions in response to the study outcomes [2]